{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&writtenParliamentaryQuestionType=Ordinary", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptShortName=Health&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&writtenParliamentaryQuestionType=Ordinary", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&_metadata=all&writtenParliamentaryQuestionType=Ordinary", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health&_page=0&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&writtenParliamentaryQuestionType=Ordinary", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&writtenParliamentaryQuestionType=Ordinary", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&writtenParliamentaryQuestionType=Ordinary", "items" : [{"_about" : "http://data.parliament.uk/resources/167080", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/167080/answer", "answerText" : {"_value" : "<p>There are an estimated 250,000 people with <ins class=\"ministerial\">the<\/ins> sickle cell <ins class=\"ministerial\">trait<\/ins> <del class=\"ministerial\">anaemia<\/del> in the United Kingdom. The Department has made no estimation of the annual cost of treating sickle cell anaemia in the National Health Service nor does it hold information on the total NHS spend on sickle cell anaemia.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The Department does hold estimated costs for admitted patient care episodes as reported by Healthcare Resource Groups. In 2013-14 the total estimated figure for sickle anaemia was £23.8 million; in 2012-13 it was £21.9 million. This figure does not include other costs such as primary and social care.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-12-08", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/167080/answer/previousversion/32239", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
          }
          , "answeringMemberConstituency" : {"_value" : "Battersea"}
          , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-12-08T15:12:22.95Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-12-10T16:29:44.707Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-12-01", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sickle Cell Diseases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much the NHS spends on sickle cell anaemia; and what proportion this is of the total NHS budget.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1587", "label" : {"_value" : "Biography information for Pat McFadden"}
      }
      , "tablingMemberConstituency" : {"_value" : "Wolverhampton South East"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Pat McFadden"}
      ], "uin" : "216527"}
    , {"_about" : "http://data.parliament.uk/resources/167082", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/167082/answer", "answerText" : {"_value" : "<p>There are an estimated 250,000 people with <ins class=\"ministerial\">the<\/ins> sickle cell <ins class=\"ministerial\">trait<\/ins> <del class=\"ministerial\">anaemia<\/del> in the United Kingdom. The Department has made no estimation of the annual cost of treating sickle cell anaemia in the National Health Service nor does it hold information on the total NHS spend on sickle cell anaemia.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The Department does hold estimated costs for admitted patient care episodes as reported by Healthcare Resource Groups. In 2013-14 the total estimated figure for sickle anaemia was £23.8 million; in 2012-13 it was £21.9 million. This figure does not include other costs such as primary and social care.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-12-08", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/167082/answer/previousversion/32239", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
          }
          , "answeringMemberConstituency" : {"_value" : "Battersea"}
          , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-12-08T15:12:22.81Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-12-10T16:29:44.707Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-12-01", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sickle Cell Diseases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the annual cost to the NHS of treating sickle cell anaemia.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1587", "label" : {"_value" : "Biography information for Pat McFadden"}
      }
      , "tablingMemberConstituency" : {"_value" : "Wolverhampton South East"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Pat McFadden"}
      ], "uin" : "216529"}
    , {"_about" : "http://data.parliament.uk/resources/105978", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/105978/answer", "answerText" : {"_value" : "<p><del class=\"ministerial\">The Civil Service Commission publish details of appointments made by exception and approved by them in their annual reports and on their website. These reports are available in the Library.<\/del><\/p><p><br /><del class=\"ministerial\">It would not be appropriate to publish details of the requests turned down by the Commission as the numbers involved are small, and the individuals might be personally identified, directly or in combination with other published information.<\/del><\/p><p> <\/p><p><ins class=\"ministerial\">The Department does not operate an \u2018Instant Rewards\u2019 scheme. The Department does, however, operate an in-year bonus scheme, which has strict criteria, approval processes and budgetary control.<\/ins><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
        }
        , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
        , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
        , "dateOfAnswer" : {"_value" : "2014-11-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/105978/answer/previousversion/27280", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
          }
          , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
          , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-11-10T16:58:06.487Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-10T17:38:55.2793146Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-11-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pay"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how many Instant Rewards of what value were given to his Department's officials in (a) 2013 and (b) 2014 to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3917", "label" : {"_value" : "Biography information for Lord Walney"}
      }
      , "tablingMemberConstituency" : {"_value" : "Barrow and Furness"}
      , "tablingMemberPrinted" : [{"_value" : "John Woodcock"}
      ], "uin" : "213068"}
    , {"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : "<p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p><p> <\/p><p> <\/p><p> <\/p><p><em>£ million<\/em><\/p><p> <\/p><table><tbody><tr><td> <\/td><td><p>2009-10<\/p><\/td><td><p>2010-11<\/p><\/td><td><p>2011-12<\/p><\/td><td><p>2012-13<\/p><\/td><td><p>2013-14<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Asthma<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p><del class=\"ministerial\">22.2 <\/del><ins class=\"ministerial\">6.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.5 <\/del><ins class=\"ministerial\">5.3<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.2<\/del><ins class=\"ministerial\"> 4.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.4<\/del><ins class=\"ministerial\"> 3.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">18.8<\/del><ins class=\"ministerial\"> 5.4<\/ins><\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.3<\/p><\/td><td><p>1.5<\/p><\/td><td><p>0.8<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>2.6<\/p><\/td><td><p>3.4<\/p><\/td><td><p>2.4<\/p><\/td><td><p>3.4<\/p><\/td><td><p>3.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p><del class=\"ministerial\">24.8<\/del><ins class=\"ministerial\"> 9.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">21.0<\/del><ins class=\"ministerial\"> 8.8<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.9<\/del><ins class=\"ministerial\"> 7.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">24.3 <\/del><ins class=\"ministerial\">8.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">23.4<\/del> <ins class=\"ministerial\">10.0<\/ins><\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Motor Neurone Research<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>7.0<\/p><\/td><td><p>7.5<\/p><\/td><td><p>4.2<\/p><\/td><td><p>4.1<\/p><\/td><td><p>3.6<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.5<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>7.3<\/p><\/td><td><p>7.8<\/p><\/td><td><p>5.0<\/p><\/td><td><p>5.5<\/p><\/td><td><p>5.1<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Osteoporosis<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>6.2<\/p><\/td><td><p>5.4<\/p><\/td><td><p>5.1<\/p><\/td><td><p>4.6<\/p><\/td><td><p>5.9<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.3<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.8<\/p><\/td><td><p>1.3<\/p><\/td><td><p>1.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>6.5<\/p><\/td><td><p>6.1<\/p><\/td><td><p>6.0<\/p><\/td><td><p>6.3<\/p><\/td><td><p>8.7<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Osteoporosis"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester West"}
      , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
      ], "uin" : "211732"}
    , {"_about" : "http://data.parliament.uk/resources/100723", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100723/answer", "answerText" : {"_value" : "<p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p><p> <\/p><p> <\/p><p> <\/p><p><em>£ million<\/em><\/p><p> <\/p><table><tbody><tr><td> <\/td><td><p>2009-10<\/p><\/td><td><p>2010-11<\/p><\/td><td><p>2011-12<\/p><\/td><td><p>2012-13<\/p><\/td><td><p>2013-14<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Asthma<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p><del class=\"ministerial\">22.2 <\/del><ins class=\"ministerial\">6.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.5 <\/del><ins class=\"ministerial\">5.3<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.2<\/del><ins class=\"ministerial\"> 4.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.4<\/del><ins class=\"ministerial\"> 3.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">18.8<\/del><ins class=\"ministerial\"> 5.4<\/ins><\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.3<\/p><\/td><td><p>1.5<\/p><\/td><td><p>0.8<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>2.6<\/p><\/td><td><p>3.4<\/p><\/td><td><p>2.4<\/p><\/td><td><p>3.4<\/p><\/td><td><p>3.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p><del class=\"ministerial\">24.8<\/del><ins class=\"ministerial\"> 9.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">21.0<\/del><ins class=\"ministerial\"> 8.8<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.9<\/del><ins class=\"ministerial\"> 7.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">24.3 <\/del><ins class=\"ministerial\">8.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">23.4<\/del> <ins class=\"ministerial\">10.0<\/ins><\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Motor Neurone Research<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>7.0<\/p><\/td><td><p>7.5<\/p><\/td><td><p>4.2<\/p><\/td><td><p>4.1<\/p><\/td><td><p>3.6<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.5<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>7.3<\/p><\/td><td><p>7.8<\/p><\/td><td><p>5.0<\/p><\/td><td><p>5.5<\/p><\/td><td><p>5.1<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Osteoporosis<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>6.2<\/p><\/td><td><p>5.4<\/p><\/td><td><p>5.1<\/p><\/td><td><p>4.6<\/p><\/td><td><p>5.9<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.3<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.8<\/p><\/td><td><p>1.3<\/p><\/td><td><p>1.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>6.5<\/p><\/td><td><p>6.1<\/p><\/td><td><p>6.0<\/p><\/td><td><p>6.3<\/p><\/td><td><p>8.7<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100723/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Motor Neurone Disease: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester West"}
      , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
      ], "uin" : "211734"}
    , {"_about" : "http://data.parliament.uk/resources/100728", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100728/answer", "answerText" : {"_value" : "<p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p><p> <\/p><p> <\/p><p> <\/p><p><em>£ million<\/em><\/p><p> <\/p><table><tbody><tr><td> <\/td><td><p>2009-10<\/p><\/td><td><p>2010-11<\/p><\/td><td><p>2011-12<\/p><\/td><td><p>2012-13<\/p><\/td><td><p>2013-14<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Asthma<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p><del class=\"ministerial\">22.2 <\/del><ins class=\"ministerial\">6.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.5 <\/del><ins class=\"ministerial\">5.3<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.2<\/del><ins class=\"ministerial\"> 4.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.4<\/del><ins class=\"ministerial\"> 3.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">18.8<\/del><ins class=\"ministerial\"> 5.4<\/ins><\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.3<\/p><\/td><td><p>1.5<\/p><\/td><td><p>0.8<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>2.6<\/p><\/td><td><p>3.4<\/p><\/td><td><p>2.4<\/p><\/td><td><p>3.4<\/p><\/td><td><p>3.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p><del class=\"ministerial\">24.8<\/del><ins class=\"ministerial\"> 9.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">21.0<\/del><ins class=\"ministerial\"> 8.8<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.9<\/del><ins class=\"ministerial\"> 7.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">24.3 <\/del><ins class=\"ministerial\">8.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">23.4<\/del> <ins class=\"ministerial\">10.0<\/ins><\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Motor Neurone Research<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>7.0<\/p><\/td><td><p>7.5<\/p><\/td><td><p>4.2<\/p><\/td><td><p>4.1<\/p><\/td><td><p>3.6<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.5<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>7.3<\/p><\/td><td><p>7.8<\/p><\/td><td><p>5.0<\/p><\/td><td><p>5.5<\/p><\/td><td><p>5.1<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Osteoporosis<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>6.2<\/p><\/td><td><p>5.4<\/p><\/td><td><p>5.1<\/p><\/td><td><p>4.6<\/p><\/td><td><p>5.9<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.3<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.8<\/p><\/td><td><p>1.3<\/p><\/td><td><p>1.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>6.5<\/p><\/td><td><p>6.1<\/p><\/td><td><p>6.0<\/p><\/td><td><p>6.3<\/p><\/td><td><p>8.7<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100728/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Motor Neurone Disease"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester West"}
      , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
      ], "uin" : "211730"}
    , {"_about" : "http://data.parliament.uk/resources/100730", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100730/answer", "answerText" : {"_value" : "<p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p><p> <\/p><p> <\/p><p> <\/p><p><em>£ million<\/em><\/p><p> <\/p><table><tbody><tr><td> <\/td><td><p>2009-10<\/p><\/td><td><p>2010-11<\/p><\/td><td><p>2011-12<\/p><\/td><td><p>2012-13<\/p><\/td><td><p>2013-14<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Asthma<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p><del class=\"ministerial\">22.2 <\/del><ins class=\"ministerial\">6.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.5 <\/del><ins class=\"ministerial\">5.3<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.2<\/del><ins class=\"ministerial\"> 4.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.4<\/del><ins class=\"ministerial\"> 3.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">18.8<\/del><ins class=\"ministerial\"> 5.4<\/ins><\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.3<\/p><\/td><td><p>1.5<\/p><\/td><td><p>0.8<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>2.6<\/p><\/td><td><p>3.4<\/p><\/td><td><p>2.4<\/p><\/td><td><p>3.4<\/p><\/td><td><p>3.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p><del class=\"ministerial\">24.8<\/del><ins class=\"ministerial\"> 9.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">21.0<\/del><ins class=\"ministerial\"> 8.8<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.9<\/del><ins class=\"ministerial\"> 7.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">24.3 <\/del><ins class=\"ministerial\">8.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">23.4<\/del> <ins class=\"ministerial\">10.0<\/ins><\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Motor Neurone Research<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>7.0<\/p><\/td><td><p>7.5<\/p><\/td><td><p>4.2<\/p><\/td><td><p>4.1<\/p><\/td><td><p>3.6<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.5<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>7.3<\/p><\/td><td><p>7.8<\/p><\/td><td><p>5.0<\/p><\/td><td><p>5.5<\/p><\/td><td><p>5.1<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Osteoporosis<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>6.2<\/p><\/td><td><p>5.4<\/p><\/td><td><p>5.1<\/p><\/td><td><p>4.6<\/p><\/td><td><p>5.9<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.3<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.8<\/p><\/td><td><p>1.3<\/p><\/td><td><p>1.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>6.5<\/p><\/td><td><p>6.1<\/p><\/td><td><p>6.0<\/p><\/td><td><p>6.3<\/p><\/td><td><p>8.7<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100730/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Osteoporosis: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester West"}
      , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
      ], "uin" : "211735"}
    , {"_about" : "http://data.parliament.uk/resources/100186", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100186/answer", "answerText" : {"_value" : "<p>Missed or inadequate hydrocortisone administration is not currently included in the list of \u2018never events\u2019.<\/p><p> <\/p><p> <\/p><p> <\/p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100186/answer/previousversion/24770", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
          }
          , "answeringMemberConstituency" : {"_value" : "Battersea"}
          , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-28T15:28:25.797Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-10-28T16:30:53.2329022Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Patients: Safety"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/95", "label" : {"_value" : "Biography information for Mr Andrew Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Oxford East"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Andrew Smith"}
      ], "uin" : "211233"}
    , {"_about" : "http://data.parliament.uk/resources/92843", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/92843/answer", "answerText" : {"_value" : "<p>The Health and Social Care Information Centre General and Personal Medical Services workforce census shows the number of general practitioners (GPs) by age band and gender working in the NHS in England as at 30 September each year.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The attached table shows the number of GPs (excluding registrars and retainers) but including GP providers (partners) and GP others (salaried) by age band and gender as at 30 September 2013 working in the NHS in England.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
        }
        , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
        , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
        , "attachment" : {"_about" : "http://data.parliament.uk/resources/92843/answer/attachment/1", "fileName" : {"_value" : "PQ210052 GPs by age band.xlsx"}
          , "title" : "GPs by Age Band Sept 2013"}
        , "dateOfAnswer" : {"_value" : "2014-10-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/92843/answer/previousversion/23112", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
          }
          , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
          , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-20T16:41:38.003Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-10-20T16:54:36.8350775Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "General Practitioners"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how many GPs working in the NHS aged (a) 25 to 35, (b) 35 to 45, (c) 45 to 55 and (d) 55 to 65 years old are (i) male and (ii) female.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/534", "label" : {"_value" : "Biography information for Chris Ruane"}
      }
      , "tablingMemberConstituency" : {"_value" : "Vale of Clwyd"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Ruane"}
      ], "uin" : "210052"}
    , {"_about" : "http://data.parliament.uk/resources/92595", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/92595/answer", "answerText" : {"_value" : "<p>Effective sharing of patient information between organisations as part of a person\u2019s direct care has enormous potential to improve patient care, services and treatments and can only be done effectively if patients are given a say over how their personal information is used.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The sharing of patient information, whilst protecting confidentiality, ensures the highest standards of care and clinical safety are consistently met throughout the National Health Service and where standards drop, allowing prompt action to be taken. It also helps to understand what happens to people, especially those with long term conditions, who are cared for away from hospital, and to ensure their needs are met and provides vital information needed to assist and support research into new medicines, and the better treatment of disease.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
        }
        , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
        , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
        , "dateOfAnswer" : {"_value" : "2014-10-17", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/92595/answer/previousversion/22453", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-17T08:53:07.013Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-10-17T09:05:53.0362001Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Records: Databases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the potential benefits to the NHS of increasing the extent to which patient-level data is shared between organisations; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/204", "label" : {"_value" : "Biography information for Paul Burstow"}
      }
      , "tablingMemberConstituency" : {"_value" : "Sutton and Cheam"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Burstow"}
      ], "uin" : "209873"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health&_page=1&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&writtenParliamentaryQuestionType=Ordinary", "page" : 0, "startIndex" : 1, "totalResults" : 15, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}